TheEdgeResearch
Home / Stocks / ATRX

Adhera Therapeutics Inc (ATRX)

OTC Healthcare Biotechnology
$0.00 ▲ +0.00%
Market Cap
$722
Sector
Healthcare
Industry
Biotechnology
Beta
873.86
52-Wk Range
0.0001-0.01
CEO
David A. Battat
Country
US
Currency
USD

Adhera Therapeutics Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in Baton Rouge, LA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $722. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of 873.86 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.00
Price / Sales
0.00
Price / Book
-0.00
EV / EBITDA
-5.29
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
-0.39
Current ratio
0.00
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
2
IPO date
1993-12-07
Headquarters
Baton Rouge, LA, US
About Adhera Therapeutics Inc

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson’s disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

Comparable companies

Adhera Therapeutics Inc is most often compared with the following Healthcare names:

CALACNNXFEFTRGBIMIMRSQIMVIFMOTSONCSQPJETPROT
More research on ATRX
ATRX technical analysis ATRX TheEdge Score Compare against peers
Open full interactive analysis & DCF →